Doximity (DOCS) · Health Care
Doximity Q1 FY2027 earnings: summary, key numbers & outlook
Results filed 6 Aug 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Doximity's clinical AI assistant Ask ranked as the top U.S.-based model on the NOHARM benchmark, while workflow active prescriber growth topped 30% year-over-year.
Doximity pushed further into AI-assisted clinical work this quarter. Its assistant Ask (formerly DoxGPT) was the top-performing U.S.-based model in the NOHARM benchmark, and AI Search queries grew over 25% quarter-over-quarter. Providers who use workflow tools such as Dialer, Scribe, Amion, PeerCheck and Ask grew more than 30% year-over-year. Management also points to early wins in innovation budgets and in pharma, where it says it offers a lower-cost option.
Management is positioning AI as the next chapter of the doctor's digital platform, a network that reaches more than 85% of U.S. physicians. The tension is competition and cost. Scribe competes against Microsoft in a crowded market, and the AI push comes with sharply higher R&D and cost of revenue. That is squeezing margins while the company tries to convert engagement into revenue.
No call transcript for this quarter, so this summary also draws on: The Motley Fool (via Webull) ↗.
Key numbers
- Revenue · GAAP
- $156.6 million
- Net income · GAAP
- $24.3 million
- Diluted EPS · GAAP
- $0.13
- Non-GAAP diluted EPS · non-GAAP
- $0.29
- GAAP gross margin · GAAP
- 84.9%
- Income from operations · GAAP
- 33.6M
- Operating cash flow
- $42.0 million
- Free cash flow · non-GAAP
- $39.6 million
up 7% year-over-year
versus $53.3 million a year ago
versus $0.27 a year ago
versus $0.36 a year ago
versus 89.2% a year ago
versus 54,517 a year ago
a decrease of 32% year-over-year
a decrease of 34% year-over-year
| Segment or metric | Value | Change |
|---|---|---|
| Workflow active prescriber growth | more than 30% | year-over-year |
| AI Search query growth | over 25% | quarter-over-quarter |
| Share of U.S. physicians in network | more than 85% |
Where each number comes from
- Revenue: “Revenue: Revenue of $156.6 million, versus $145.9 million, an increase of 7% year-over-year.”
- Net income: “Net income of $24.3 million, versus $53.3 million, representing a margin of 15.5%, versus 36.5%.”
- Diluted EPS: “Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.”
- Non-GAAP diluted EPS: “Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.”
- GAAP gross margin: “GAAP gross margin | 84.9% | 89.2% Non-GAAP gross margin | 87.5% | 91.2%”
- Income from operations: “Total operating expenses | 99,282 | 75,603 Income from operations | 33,644 | 54,517 Other income, net | 6,719 | 9,630”
- Operating cash flow: “Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million”
- Free cash flow: “Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million, versus $60.1 million”
- Workflow active prescriber growth: “workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter”
- AI Search query growth: “workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter”
- Share of U.S. physicians in network: “The company's network members include more than 85% of U.S. physicians across all specialties and practice areas.”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q1 FY2027 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $156.6M | +7.3% | +7.7% |
| Operating income | $33.6M | −38.3% | +35.5% |
| Net income | $24.3M | −54.4% | +27.2% |
| Diluted EPS | $0.13 | −51.9% | — |
| Free cash flow | $41.9M | −32.5% | — |
| Gross margin | 84.9% | −4.3 pts | −1.8 pts |
| Operating margin | 21.5% | −15.9 pts | +4.4 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Revenue | fiscal second quarter ending September 30, 2026 | between $170 million and $171 million |
| Adjusted EBITDA | fiscal second quarter ending September 30, 2026 | between $80.5 million and $81.5 million |
| Revenue | fiscal year ending March 31, 2027 | between $671 million and $681 million |
| Adjusted EBITDA | fiscal year ending March 31, 2027 | between $309 million and $329 million |
Key takeaways
Ask tops U.S.-based models on NOHARM benchmark
Doximity says its clinical AI assistant, Ask, was the top-performing U.S.-based model in the NOHARM benchmark. Independent safety-style validation supports trust with clinicians and buyers.
Workflow active prescribers grew more than 30%
Workflow active prescriber growth exceeded 30% year-over-year. The metric counts providers using tools such as Dialer, fax, Ask, PeerCheck, Amion and Scribe, so it shows adoption beyond the core network.
AI Search queries up over 25% sequentially
AI Search query growth was over 25% quarter-over-quarter. Rapid usage growth gives Doximity a high-intent audience for new AI products and for pharma customers.
AI Search is opening innovation and pharma budgets
Management says AI Search is starting to win innovation budget, and that pharma has been a surprise source of added market opportunity. It is entering with a lower-cost offering than what customers may have used before.
AI investment is weighing on margins
R&D, sales and marketing, and cost of revenue all rose faster than revenue, and stock-based compensation climbed. Net income margin fell to 15.5% from 36.5%, so the cost of building clinical AI is itself part of the story.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q3 FY25 | $168.6M |
| Q4 FY25 | $138.3M * |
| Q1 FY26 | $145.9M |
| Q2 FY26 | $168.5M |
| Q3 FY26 | $185.1M |
| Q4 FY26 | $145.4M * |
| Q1 FY27 | $156.6M |
| Q2 FY27 | $174.5M |
Data
| Q3 FY25 | $0.37 |
| Q1 FY26 | $0.27 |
| Q2 FY26 | $0.31 |
| Q3 FY26 | $0.31 |
| Q1 FY27 | $0.13 |
| Q2 FY27 | $0.18 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q3 FY25 | 47.4% |
| Q4 FY25 | 35.2% |
| Q1 FY26 | 37.4% |
| Q2 FY26 | 37.8% |
| Q3 FY26 | 38.9% |
| Q4 FY26 | 17.1% |
| Q1 FY27 | 21.5% |
| Q2 FY27 | 25.2% |
Data
| Q3 FY25 | $65.2M |
| Q4 FY25 | $98.5M |
| Q1 FY26 | $62.1M |
| Q2 FY26 | $93.9M |
| Q1 FY27 | $41.9M |
| Q2 FY27 | $93.3M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What was Doximity's main product highlight this quarter?
Its clinical AI assistant, Ask, was the top-performing U.S.-based model in the NOHARM benchmark. Management paired this with record engagement.
How is customer and clinician usage trending?
Workflow active prescriber growth was more than 30% year-over-year, and AI Search query growth was over 25% quarter-over-quarter. Doximity's network includes more than 85% of U.S. physicians.
Where is new demand for Doximity's AI products coming from?
Management says AI Search is starting to win innovation budget at health systems, and that pharma has been an unexpected opportunity. It is pitching pharma a lower-cost offering than customers may have used before.
Who does Doximity compete with in AI?
In the ambient scribe market, management names Microsoft as the leader. Doximity competes with Scribe, its HIPAA-compliant ambient note-taking tool, and with Ask, its clinical AI assistant.
What is the tradeoff in Doximity's AI strategy?
Management says it can still post strong software margins while investing heavily in clinical AI. Even so, R&D and cost of revenue rose faster than revenue, and margins fell from a year ago.
Documents
From Doximity investor relations
SEC filing